Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
- PMID: 22666204
- PMCID: PMC3364096
- DOI: 10.1159/000338040
Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
Abstract
The treatment of lymphomas may result in the development of second malignancies, as evident by the numerous reports in the literature. Treatment with cyclophosphamide-based chemotherapy regimens may lead to bladder lesions such as haemorrhagic cystitis and also to carcinoma of the urinary bladder. Previous pelvic radiotherapy treatment is also implicated as a cause for local second cancers. We present the case of a patient treated for Hodgkin's lymphoma, who was diagnosed with transitional cell carcinoma of the bladder soon after treatment completion. On completion of 6 cycles of ABVD chemotherapy the patient was on follow-up. Two months after treatment completion the patient complained of dysuria and was investigated for a suspected urinary tract infection. Urine microscopy did not reveal any abnormality. Symptomatic treatment was prescribed and cystoscopy was arranged. The cystoscopic findings suggested an irregular growth overlying the trigone and the biopsy reported it as transitional cell carcinoma. This case report demonstrates that symptoms attributed to common medical causes in patients treated for cancer may be a sign of second malignancy. This case report also demonstrates the need for a thorough evaluation of patients' complaints during follow-up, although the likelihood for the occurrence of a second malignancy may be low. The assumption that these symptoms were due to a commonly occurring urinary tract infection would have had serious implications leading to a delay in the treatment of the bladder cancer.
Keywords: ABVD; Bladder carcinoma; Chemotherapy; Hodgkin's lymphoma.
Figures
Similar articles
-
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6. Lancet Haematol. 2018. PMID: 30290903 Clinical Trial.
-
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.J Clin Oncol. 2002 Jan 15;20(2):476-84. doi: 10.1200/JCO.2002.20.2.476. J Clin Oncol. 2002. PMID: 11786577 Clinical Trial.
-
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15. Lancet Oncol. 2013. PMID: 24239220 Clinical Trial.
-
Primary Hodgkin's Lymphoma of the Sternum: Report of a Case and Review of the Literature.J Clin Diagn Res. 2016 Jun;10(6):XE07-XE10. doi: 10.7860/JCDR/2016/19666.8065. Epub 2016 Jun 1. J Clin Diagn Res. 2016. PMID: 27504392 Free PMC article. Review.
-
What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?Curr Hematol Rep. 2004 Jan;3(1):17-26. Curr Hematol Rep. 2004. PMID: 14695845 Review.
References
-
- Pathak AB, Advani SH, Gopal R, Nadkarni KS, Saikia TK. Urinary bladder cancer following cyclophosphamide therapy for Hodgkin's disease. Leuk Lymphoma. 1992;8:503–504. - PubMed
-
- Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986;4:830–837. - PubMed
-
- Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol. 1996;6:225–242. - PubMed
-
- Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–3494. - PubMed
Publication types
LinkOut - more resources
Full Text Sources